Welcome to our dedicated page for Pharmather Holdings news (Ticker: PHRRF), a resource for investors and traders seeking the latest updates and insights on Pharmather Holdings stock.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) specializes in developing novel ketamine-based therapies and advanced drug formulations for critical healthcare needs. This news hub provides investors and healthcare professionals with essential updates on the company's clinical programs, regulatory milestones, and strategic initiatives.
Access timely updates on KETARX™ clinical trials, FDA correspondence regarding ketamine production, and developments in PD-001 formulation research through Sairiyo Therapeutics. Our curated news collection covers earnings announcements, partnership agreements, manufacturing updates, and therapeutic application discoveries.
Key areas of focus include progress in addressing global anesthesia shortages, advancements in mental health treatment research, and quality control enhancements in pharmaceutical production. The resource serves as a centralized tracking tool for monitoring the company's progress through clinical development phases and regulatory review processes.
Bookmark this page for streamlined access to verified updates about PharmaTher's work in pain management innovation and neurological disorder research. Regularly updated content ensures stakeholders maintain current understanding of the company's position within the competitive pharmaceutical landscape.
PharmaTher Holdings announced receiving an Amendment Acknowledgment Letter from the FDA for its Priority Original Abbreviated New Drug Application for Ketamine, with a goal date of October 29, 2024. The company addressed FDA comments promptly to meet the goal date. PharmaTher aims to solve the ketamine shortage problem in the U.S., adhere to FDA guidelines, and expand globally. They focus on novel uses of ketamine for pain, mental health, and neurological disorders.
PharmaTher announced that its subsidiary Sairiyo Therapeutics has completed the clinical and regulatory package for a Phase 1 study of a reformulated version of cepharanthine for infectious diseases and oncology. Sairiyo plans to conduct the study in Australia and then apply for FDA approval to begin clinical trials in the United States.
FAQ
What is the current stock price of Pharmather Holdings (PHRRF)?
What is the market cap of Pharmather Holdings (PHRRF)?
